{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:25:40Z","timestamp":1793057140000,"version":"4.5.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,15]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemolytic disease of the fetus and newborn (HDFN) remains an important cause of perinatal morbidity and mortality. HDFN is caused by maternal alloimmunization to red blood cell (RBC) antigens. This article describes and highlights issues in the care of pregnant women with RBC alloimmunization. This includes monitoring for, and management of fetal anemia caused by maternal red cell alloantibodies, but also considerations for transfusion support for the woman in the event of major bleeding. Many aspects of care for women with RBC alloantibodies are not covered within specific guidelines, particularly with respect to best practice for antenatal management of women with prior significant obstetric morbidity or mortality due to HDFN, and we outline our approach in these cases. The use of noninvasive monitoring for fetal anemia through measurement of the middle cerebral artery peak systolic velocity has led to a paradigm shift in antenatal care for women with high-risk antibodies, and medical therapies hold promise for women with the most severe disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022894","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T19:42:28Z","timestamp":1715715748000},"page":"2275-2282","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["How I manage pregnant patients who are alloimmunized to RBC antigens"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-3064","authenticated-orcid":false,"given":"Helen Frances","family":"Savoia","sequence":"first","affiliation":[{"name":"1Department of Clinical Haematology, The Royal Children's Hospital, Parkville, VIC, Australia"},{"name":"2Department of Clinical Haematology The Royal Women\u2019s Hospital Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Parakh","sequence":"additional","affiliation":[{"name":"2Department of Clinical Haematology The Royal Women\u2019s Hospital Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5172-3263","authenticated-orcid":false,"given":"Stefan Charles","family":"Kane","sequence":"additional","affiliation":[{"name":"3Department of Maternal Fetal Medicine, The Royal Women's Hospital, Parkville, VIC, Australia"},{"name":"4Department of Obstetrics, Gynaecology and Newborn Health, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2025051511211001900_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.21307\/immunohematology-2019-134","article-title":"Prevalence of clinically significant\u00a0red blood cell alloantibodies in pregnant women at a large tertiary-care facility","volume":"29","author":"Smith","year":"2013","journal-title":"Immunohematol"},{"issue":"1","key":"2025051511211001900_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/asheducation-2016.1.446","article-title":"Understanding red blood cell alloimmunization triggers","volume":"2016","author":"Hendrickson","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2025051511211001900_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.tmrv.2018.07.002","article-title":"Red blood cell alloimmunization in the pregnant patient","volume":"32","author":"Webb","year":"2018","journal-title":"Transfus Med Rev"},{"key":"2025051511211001900_bib4","author":"Cohn","year":"2023","edition":"21st ed."},{"issue":"3","key":"2025051511211001900_bib5","doi-asserted-by":"crossref","first-page":"344.e1-6","DOI":"10.1016\/j.ajog.2016.03.019","article-title":"Intravenous drug use is associated with alloimmunization in pregnancy","volume":"215","author":"Lappen","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2025051511211001900_bib6","author":"Australian and New Zealand Society of Blood Transfusion Ltd","year":"2020","edition":"1st edition rev"},{"issue":"4","key":"2025051511211001900_bib7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/tme.12299","article-title":"Guideline for blood grouping and red cell antibody testing in pregnancy","volume":"26","author":"White","year":"2016","journal-title":"Transfus Med"},{"key":"2025051511211001900_bib8","article-title":"National Institute for Health and Care Excellence","year":"2021","journal-title":"NICE Guideline: Antenatal Care"},{"issue":"2","key":"2025051511211001900_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/PAT.0000000000000225","article-title":"Prevalence of maternal red cell alloimmunisation: a population study from Queensland, Australia","volume":"47","author":"Pal","year":"2015","journal-title":"Pathology"},{"issue":"3","key":"2025051511211001900_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/tme.12399","article-title":"Prevalence of maternal alloantibodies in a large teaching hospital and their impact on outcomes of fetuses\/neonates","volume":"27","author":"Ainley","year":"2017","journal-title":"Transfus Med"},{"issue":"5","key":"2025051511211001900_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1537-2995.2007.01625.x","article-title":"Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands","volume":"48","author":"Koelewijn","year":"2008","journal-title":"Transfusion"},{"issue":"11","key":"2025051511211001900_bib12","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/trf.15987","article-title":"Red blood cell alloimmunization prevalence and hemolytic disease of the fetus and newborn in Israel: a retrospective study","volume":"60","author":"Rahimi-Levene","year":"2020","journal-title":"Transfusion"},{"key":"2025051511211001900_bib13","first-page":"283","article-title":"Prevalence and specificity of clinically significant red cell alloantibodies in pregnant women - a study from a tertiary care hospital in Southeast Michigan","volume":"10","author":"Moinuddin","year":"2019","journal-title":"J\u00a0Blood Med"},{"issue":"3","key":"2025051511211001900_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.transci.2013.04.021","article-title":"The risk assessment study for hemolytic disease of the fetus and newborn in a University Hospital in Turkey","volume":"48","author":"Altuntas","year":"2013","journal-title":"Transfus Apher Sci"},{"issue":"6s","key":"2025051511211001900_bib15","first-page":"70","article-title":"Prevalence of alloantibodies associated with haemolytic disease of the fetus and newborn in pregnant women at the Ekiti State University Teaching Hospital, Ado-Ekiti, Southwest Nigeria","volume":"27","author":"Olayanju","year":"2023","journal-title":"Afr J Reprod Health"},{"issue":"3","key":"2025051511211001900_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/trf.16276","article-title":"Reduction of anti-K-mediated hemolytic disease of newborns after the introduction of a matched transfusion policy: a nation-wide policy change evaluation study in the Netherlands","volume":"61","author":"Luken","year":"2021","journal-title":"Transfusion"},{"issue":"3","key":"2025051511211001900_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/trf.13977","article-title":"Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study","volume":"57","author":"Delaney","year":"2017","journal-title":"Transfusion"},{"issue":"2","key":"2025051511211001900_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.blre.2005.04.002","article-title":"Rh proteins: key structural and functional components of the red cell membrane","volume":"20","author":"Van Kim","year":"2006","journal-title":"Blood Rev"},{"issue":"4","key":"2025051511211001900_bib21","doi-asserted-by":"crossref","first-page":"393.e1","DOI":"10.1016\/j.ajog.2018.07.020","article-title":"Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management","volume":"219","author":"Slootweg","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2025051511211001900_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-3148.1996.d01-64.x","article-title":"The distribution of the MiIII (Gp.Mur) phenotype among the population of Taiwan","volume":"6","author":"Broadberry","year":"1996","journal-title":"Transfus Med"},{"issue":"3","key":"2025051511211001900_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-3148.1991.tb00027.x","article-title":"The MiIII phenotype among Chinese donors in Hong Kong: immunochemical and serological studies","volume":"1","author":"Poole","year":"1991","journal-title":"Transfus Med"},{"issue":"2","key":"2025051511211001900_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tmrv.2010.11.003","article-title":"Sixty\u00a0years of antibodies to MNS system hybrid glycophorins: what have we learned?","volume":"25","author":"Heathcote","year":"2011","journal-title":"Transfus Med Rev"},{"issue":"5","key":"2025051511211001900_bib25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-3148.2002.00394.x","article-title":"Hydrops foetalis caused by anti-Mur in first pregnancy--a case report","volume":"12","author":"Wu","year":"2002","journal-title":"Transfus Med"},{"key":"2025051511211001900_bib26","volume-title":"Green-Top Guideline 65: The Management of Women With Red Cell Antibodies in Pregnancy","author":"Royal College of Obstetricians and Gynaecologists","year":"2014"},{"issue":"1","key":"2025051511211001900_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/voxs.12260","article-title":"Clinical impact and prevalence of IgG1 and IgG3 subclasses in antenatal alloimmunized women: experience from a tertiary medical centre in South India","volume":"11","author":"Choudhuri","year":"2016","journal-title":"ISBT Sci Ser"},{"issue":"6","key":"2025051511211001900_bib28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ajog.2015.01.059","article-title":"Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia--diagnosis and management","volume":"212","author":"Mari","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"2025051511211001900_bib29","doi-asserted-by":"crossref","first-page":"102947","DOI":"10.1016\/j.transci.2020.102947","article-title":"Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation","volume":"59","author":"Hyland","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"2025051511211001900_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ajo.13446","article-title":"The role of non-invasive prenatal testing (NIPT) for fetal blood group typing in Australia","volume":"62","author":"Ginige","year":"2022","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"2025051511211001900_bib31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/GRF.0b013e3181fbaf6d","article-title":"Middle cerebral artery Doppler for managing fetal anemia","volume":"53","author":"Samson","year":"2010","journal-title":"Clin Obstet Gynecol"},{"issue":"6","key":"2025051511211001900_bib32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/uog.20273","article-title":"Performance of fetal middle cerebral artery peak systolic velocity for prediction of anemia in untransfused and transfused fetuses: systematic review and meta-analysis","volume":"54","author":"Martinez-Portilla","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"2","key":"2025051511211001900_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000111599","article-title":"Early intraperitoneal transfusion and adjuvant maternal immunoglobulin therapy in the treatment of severe red cell alloimmunization prior to fetal intravascular transfusion","volume":"23","author":"Fox","year":"2008","journal-title":"Fetal Diagn Ther"},{"issue":"2","key":"2025051511211001900_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/uog.17319","article-title":"Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures","volume":"50","author":"Zwiers","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"11","key":"2025051511211001900_bib35","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00431-015-2573-x","article-title":"Neonatal outcome after fetal anemia managed by intrauterine transfusion","volume":"174","author":"Garabedian","year":"2015","journal-title":"Eur J Pediatr"},{"issue":"6","key":"2025051511211001900_bib36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1479-828X.2009.01091.x","article-title":"IVIG - is it the answer? Maternal administration of immunoglobulin for severe fetal red blood cell alloimmunisation during pregnancy: a case series","volume":"49","author":"Connan","year":"2009","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"1","key":"2025051511211001900_bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.18449","article-title":"Intravenous immunoglobulin in the management of severe early onset red blood cell alloimmunisation","volume":"200","author":"Vlachodimitropoulou","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"2025051511211001900_bib38","doi-asserted-by":"crossref","first-page":"291.e1","DOI":"10.1016\/j.ajog.2018.06.007","article-title":"Postponing early intrauterine transfusion with intravenous immunoglobulin treatment; the PETIT study on severe hemolytic disease of the fetus and newborn","volume":"219","author":"Zwiers","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2025051511211001900_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"issue":"3","key":"2025051511211001900_bib40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjh.17041","article-title":"Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation","volume":"192","author":"Castleman","year":"2021","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2025051511211001900_bib41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-140558","article-title":"Immunoadsorption, intravenous immunoglobulins and rituximab (IIR): successful new treatment approach for severe anti K- alloimmunisation during pregnancy [abstract]","volume":"136","author":"Capraru","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2025051511211001900_bib42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2025051511211001900_bib43","doi-asserted-by":"crossref","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025051511211001900_bib44","author":"Moise","year":"25-29  2023"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/20\/2275\/2374640\/blood_bld-2023-022894-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/20\/2275\/2374640\/blood_bld-2023-022894-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T15:21:24Z","timestamp":1747322484000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/20\/2275\/516110\/How-I-manage-pregnant-patients-who-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":42,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022894","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}